Until now, the nucleoside derivatives 5-azacytidine and decitabine are the sole DNA methyltransferase (DNMT) inhibitors approved by the FDA for the treatment of specific hematological cancers. This evidence concerns the gene DNMT1 and hematopoietic and lymphoid cell neoplasm.